{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:46:15Z","timestamp":1792683975422,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031585","name":"Takeda Development Center Americas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031585","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.rpth.2026.106939","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:48:45Z","timestamp":1788418125000},"page":"106939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A"],"prefix":"10.1016","volume":"10","author":[{"suffix":"Jr.","given":"Robert F.","family":"Sidonio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Mullins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony K.C.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleksandra","family":"Stasyshyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoh Leng","family":"Yeoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darintr","family":"Sosothikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Bulent","family":"Antmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer S.","family":"El-Kamary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srilatha","family":"Tangada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106939_bib1","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias\u2014from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N Engl J Med"},{"issue":"Suppl 6","key":"10.1016\/j.rpth.2026.106939_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106939_bib3","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","article-title":"Haemophilias A and B","volume":"361","author":"Bolton-Maggs","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2026.106939_bib4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1016\/j.rpth.2026.106939_bib5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12959-016-0103-3","article-title":"Aspects of prophylactic treatment of hemophilia","volume":"14","author":"Ljung","year":"2016","journal-title":"Thromb J"},{"key":"10.1016\/j.rpth.2026.106939_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102265","article-title":"Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 previously untreated patients from Europe and Canada","volume":"7","author":"Fischer","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106939_bib7","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1365-2516.2007.01518.x","article-title":"European study on orthopaedic status of haemophilia patients with inhibitors","volume":"13","author":"Morfini","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106939_bib8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11096-007-9181-4","article-title":"Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres","volume":"30","author":"Nerich","year":"2008","journal-title":"Pharm World Sci"},{"key":"10.1016\/j.rpth.2026.106939_bib9","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1182\/bloodadvances.2023011475","article-title":"A post hoc analysis of previously untreated patients with severe hemophilia A who developed inhibitors in the PUPs A-LONG trial","volume":"8","author":"Carcao","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106939_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jth.13888","article-title":"Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis","volume":"16","author":"Peyvandi","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106939_bib11","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106939_bib12","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1160\/TH14-07-0621","article-title":"Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis","volume":"113","author":"Marcucci","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106939_bib13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/17474086.2023.2247160","article-title":"Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study","volume":"16","author":"Sidonio","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.rpth.2026.106939_bib14","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.thromres.2019.12.012","article-title":"Extended half-life recombinant products in haemophilia clinical practice\u2014expectations, opportunities and challenges","volume":"196","author":"Chowdary","year":"2020","journal-title":"Thromb Res"},{"issue":"suppl 1","key":"10.1016\/j.rpth.2026.106939_bib17","first-page":"S29","article-title":"BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation","volume":"32","author":"Turecek","year":"2012","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.rpth.2026.106939_bib18","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3390\/ph15080911","article-title":"Immunogenicity of current and new therapies for hemophilia A","volume":"15","author":"Prezotti","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.rpth.2026.106939_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154\u2013155","author":"Kozma","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.rpth.2026.106939_bib20","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5358272","article-title":"Posttranslational modifications and the immunogenicity of biotherapeutics","volume":"2016","author":"Jefferis","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1016\/j.rpth.2026.106939_bib21","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1160\/TH11-09-0642","article-title":"Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A","volume":"107","author":"Auerswald","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106939_bib22","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1365-2516.2010.02332.x","article-title":"Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma\/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice","volume":"16","author":"Oldenburg","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106939_bib23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0038-1653759","article-title":"The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability","volume":"73","author":"Verbruggen","year":"1995","journal-title":"Thromb Haemost"},{"issue":"suppl 2","key":"10.1016\/j.rpth.2026.106939_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1351-8216.2001.00134.x","article-title":"Inhibitor development in correlation to factor VIII genotypes","volume":"8","author":"Oldenburg","year":"2002","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106939_bib25","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106939_bib26","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1016\/j.jtha.2023.07.030","article-title":"The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia A: pathfinder6 end-of-trial results","volume":"21","author":"Kenet","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106939_bib27","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1055\/s-0040-1722623","article-title":"Simoctocog alfa (Nuwiq) in previously untreated patients with severe haemophilia A: final results of the NuProtect study","volume":"121","author":"Liesner","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106939_bib28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/hae.13320","article-title":"Immunogenicity, efficacy and safety of Nuwiq (human-cl rhFVIII) in previously untreated patients with severe haemophilia A\u2014interim results from the NuProtect study","volume":"24","author":"Liesner","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106939_bib29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/hae.13883","article-title":"Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: results from the guardian 4 multinational clinical trial","volume":"26","author":"Yaish","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106939_bib30","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/hae.15151","article-title":"Extension study with rVIII-SingleChain in previously untreated patients (PUPs) with severe haemophilia A","volume":"31","author":"Mahlangu","year":"2025","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106939_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bvth.2025.100082","article-title":"Inhibitor development and clinical characteristics in children with severe hemophilia A in the ATHN 8 US cohort study","volume":"2","author":"Thornburg","year":"2025","journal-title":"Blood Vessel Thromb Hemost"},{"key":"10.1016\/j.rpth.2026.106939_bib32","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood.2021013563","article-title":"First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results","volume":"139","author":"Konigs","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106939_bib33","author":"Guow"},{"key":"10.1016\/j.rpth.2026.106939_bib34","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/hae.12762","article-title":"Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates","volume":"22","author":"Stidl","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106939_bib35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1055\/s-0044-1791778","article-title":"Factor replacement treatment for hemophilia A: achievements and perspectives","volume":"51","author":"Mancuso","year":"2025","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2026.106939_bib36","doi-asserted-by":"crossref","first-page":"100194","DOI":"10.1016\/j.bvth.2026.100194","article-title":"Decoding full-length factor VIII through the structural and functional lens of its B-domain","author":"Ramaraje Urs","year":"2026","journal-title":"Blood Vessels Thromb. Hemost"},{"key":"10.1016\/j.rpth.2026.106939_bib37","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1007\/s00216-015-8778-z","article-title":"Ca(2+) concentration-dependent conformational change of FVIII B-domain observed by atomic force microscopy","volume":"407","author":"Bonazza","year":"2015","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.rpth.2026.106939_bib38","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jtha.2023.03.011","article-title":"Antidrug antibodies against the polyethylene glycol moiety inhibit the procoagulant activity of therapeutic polyethylene glycolated factor VIII","volume":"21","author":"Pezeshkpoor","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106939_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.894411","article-title":"Polyethylene glycol 20 kDa-induced vacuolation does not impair phagocytic function of human monocyte-derived macrophages","volume":"13","author":"Schoenbrunn","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.rpth.2026.106939_bib40","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.2147\/DDDT.S481420","article-title":"Optimizing pharmacological and immunological properties of therapeutic proteins through PEGylation: investigating key parameters and their impact","volume":"18","author":"Goncalves","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.rpth.2026.106939_bib41","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40259-024-00684-z","article-title":"Adverse impacts of PEGylated protein therapeutics: a targeted literature review","volume":"38","author":"Lee","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.rpth.2026.106939_bib42","author":"Takeda Manufacturing Austria"},{"key":"10.1016\/j.rpth.2026.106939_bib43","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/hae.14796","article-title":"Long-term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study in previously untreated patients","volume":"29","author":"Mathias","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106939_bib44","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/ejh.14040","article-title":"Simoctocog alfa (Nuwiq\u00ae) in previously untreated patients with severe haemophilia A\u2014final efficacy and safety results from the NuProtect study","volume":"111","author":"Mathias","year":"2023","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.rpth.2026.106939_bib45","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood.2023021832","article-title":"Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial","volume":"143","author":"Pipe","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106939_bib46","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106939_bib47","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106939_bib48","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1538-7836.2011.04611.x","article-title":"A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management","volume":"10","author":"Valentino","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106939_bib49","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2217\/cer-2021-0109","article-title":"Real-world treatment, clinical outcomes and healthcare resource utilization among persons with hemophilia A by age","volume":"10","author":"Caplan","year":"2021","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.rpth.2026.106939_bib50","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood.2020005673","article-title":"Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study","volume":"137","author":"Klamroth","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106939_bib51","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/hae.13119","article-title":"Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A","volume":"23","author":"Mullins","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106939_bib52","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1182\/bloodadvances.2023011780","article-title":"Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A","volume":"8","author":"Horling","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106939_bib53","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3390\/ph15101183","article-title":"Updates on novel non-replacement drugs for hemophilia","volume":"15","author":"Gualtierotti","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.rpth.2026.106939_bib54","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/bloodadvances.2019000849","article-title":"Laboratory monitoring of hemophilia A treatments: new challenges","volume":"4","author":"Lenting","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106939_bib55","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/08880018.2021.2004269","article-title":"Breakthrough bleeding episodes in pediatric severe hemophilia A patients with and without inhibitors receiving emicizumab prophylaxis: a single-center retrospective review","volume":"39","author":"Hassan","year":"2022","journal-title":"Pediatr Hematol Oncol"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:23:50Z","timestamp":1792682630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926035971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2475037926035971"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106939","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106939","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106939"}}